Shuyan Gu
Overview
Explore the profile of Shuyan Gu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
743
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hu X, Gu S, Zhen X, Sun X, Gu Y, Dong H
Front Public Health
. 2021 Dec;
9:753671.
PMID: 34900900
To investigate the effects of age, period, and cohort (APC) on trends in cognitive function among the Chinese elderly, and to explore how gender gaps in cognitive function change with...
12.
Bai L, Gu S, Gu H, Xu X, Nan C, Li D, et al.
Inquiry
. 2021 May;
58:469580211018283.
PMID: 34027690
This paper discussed the influence of disability and the degree of disability on the intergenerational needs of the elderly in terms of time and economy. The data is from the...
13.
Sun X, Zhen X, Hu X, Li Y, Gu S, Gu Y, et al.
Ann Transl Med
. 2021 May;
9(7):575.
PMID: 33987273
Background: The objective of this study is to compare the long-term cost-utility of imrecoxib and celecoxib for patients with osteoarthritis (OA) from the perspective of the Chinese healthcare system. Methods:...
14.
Sun X, Zhen X, Hu X, Li Y, Gu S, Gu Y, et al.
Cost Eff Resour Alloc
. 2021 Apr;
19(1):22.
PMID: 33879168
Background: To estimate the cost -utility of imrecoxib compared with diclofenac, as well as the addition of a proton pump inhibitor to both two treatment strategies, for patients with osteoarthritis,...
15.
Zhen X, Stalsby Lundborg C, Sun X, Zhu N, Gu S, Dong H
Antimicrob Resist Infect Control
. 2021 Apr;
10(1):64.
PMID: 33795000
No abstract available.
16.
Zhen X, Stalsby Lundborg C, Sun X, Zhu N, Gu S, Dong H
Antimicrob Resist Infect Control
. 2021 Jan;
10(1):5.
PMID: 33407856
Background: Antibiotic resistance (AR) threats public health in China. National-level estimation of economic burden of AR is lacking. We aimed to quantify the economic costs of AR in inpatients in...
17.
Gu S, Shi L, Shao H, Wang X, Hu X, Gu Y, et al.
BMC Med
. 2020 Dec;
18(1):378.
PMID: 33267884
Background: Clinical guidelines recommend a stepped-escalation treatment strategy for type 2 diabetes (T2DM). Across multiple treatment strategies varying in efficacy and costs, no clinical or economic studies directly compared them....
18.
Zhen X, Stalsby Lundborg C, Sun X, Gu S, Dong H
Antibiotics (Basel)
. 2020 Aug;
9(8).
PMID: 32823707
Carbapenem resistant (CRKP), (CRPA), and (CRAB) pose significant threats to public health. However, the clinical and economic impacts of CRKP, CRPA, and CRAB remain largely uninvestigated in China. This study...
19.
Gu S, Wang X, Shi L, Sun Q, Hu X, Gu Y, et al.
Qual Life Res
. 2020 May;
29(10):2695-2704.
PMID: 32410144
Purpose: To estimate the health-related quality of life (HRQoL) of type 2 diabetes (T2DM) inpatients hospitalized for a complication in China and to explore the associated factors. Methods: This was...
20.
Zhen X, Stalsby Lundborg C, Zhang M, Sun X, Li Y, Hu X, et al.
Sci Rep
. 2020 Mar;
10(1):3900.
PMID: 32127606
Methicillin-resistant Staphylococcus aureus (MRSA) has become a serious threat to global health. In China, the proportion of S. aureus isolates that were MRSA was 44.6% in 2014. The clinical and...